Pharmaceuticals News and Research

RSS

WHO aims to improve injection safety across the globe

In an effort to improve injection safety across the globe, the World Health Organization (WHO) has began a 3-day meeting with experts to explore strategies aimed at promoting the use of safer needles.

24 Oct 2007

Influenza vaccine production capacity on the rise

Recent scientific advances and increased vaccine manufacturing capacity have prompted experts to increase their projections of how many pandemic influenza vaccine courses can be made available in the coming years.

24 Oct 2007

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.

24 Oct 2007

Mylan settles Paroxetine Hydrochloride patent license with GlaxoSmithKline

Mylan Inc. has announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GSK's Paxil CR.

24 Oct 2007

Experimental cancer pharmaceuticals under trial

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

24 Oct 2007

In the event of a bird flu pandemic more vaccine will be ready

The World Health Organization (WHO) has revised it's estimate of how much bird flu vaccine could be available were a pandemic scenario to unfold.

24 Oct 2007

Advances in drug screening

With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets.

23 Oct 2007

Cellular power plant fault explains abnormal metabolism of tumours

The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.

23 Oct 2007

New method of oral insulin delivery patented

Syracuse University researchers have designed, tested and patented a new method of oral insulin delivery that can potentially help reduce daily insulin injections for millions of people with diabetes who require therapy for optimal glycemic control.

22 Oct 2007

Funding source a major determinant in findings regarding adverse effects in corticosteroid studies

Studies of inhaled corticosteroids, medications frequently prescribed for asthma and other respiratory problems, appear less likely to find adverse effects if they are funded by pharmaceutical companies than if they are funded by other sources, according to a report in the October 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

22 Oct 2007

Breakthrough reveals important human receptor structure that will aid drug development

Scientists at the MRC Laboratory of Molecular Biology (LMB) in Cambridge have obtained the first clear images of the proteins that relay vital messages to cells.

22 Oct 2007

Adenoscan patent lawsuits settled

Astellas Pharma Inc., King Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. have announced that U.S. subsidiaries of Astellas, along with Item Development AB and King have executed settlement agreements with one of Teva's subsidiaries on lawsuits filed in the United States against Teva's subsidiaries regarding their submission of an abbreviated new drug application (ANDA) for a generic version of Adenoscan (adenosine injection), a pharmacologic stress agent.

22 Oct 2007

MDS Nordion signs 17-year contract with Rosenergoatom for cobalt-60

MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, signed a 17-year contract for the supply of cobalt-60 with Rosenergoatom, the operating utility of Russia's nuclear power plants.

22 Oct 2007

Little evidence to support therapies for post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is a severe and ongoing emotional reaction to an extreme psychological trauma; it affects significant numbers of people, in particular military personnel and veterans, who have seen active duty in war zones.

22 Oct 2007

Effective vaccine against malaria a very real possibility

The preliminary results of a malaria vaccine trial in African infants show that the vaccine gave a high level of protection and was also safe.

19 Oct 2007

Review of PTSD treatments

Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.

19 Oct 2007

Comparing public and private health insurance

The Manhattan Institute has released a new report by senior fellow Benjamin Zycher, entitled "Comparing Public and Private Health Insurance: Would a Single-Payer System Save Enough to Cover the Uninsured?" In it, Zycher dispels a common misconception regarding single-payer health insurance.

19 Oct 2007